EGFR and neoplasm: Therefore, this study aimed to explore the prognostic power of the combination of systemic inflammation markers and tumor glycolytic heterogeneity for the risk stratification of patients with advanced EGFR-mutated lung adenocarcinoma treated with a first-line TKI.